BioSpyder Advances Single-Cell Genomics with Launch of TempO-LINC Platform
BioSpyder, a leader in molecular biology assays, introduces TempO-LINC, a proprietary high-throughput single-cell genomics platform. TempO-LINC marks a significant advancement in the field, offering a fundamentally different approach to single-cell genomics based on the foundational TempO-Seq technology developed by BioSpyder for gene expression analysis.
TempO-LINC is differentiated from traditional mRNA reverse transcription-based approaches by its utilization of high-sensitivity detector oligos (DOs). These DOs specifically hybridize to two immediately adjacent regions within an expressed transcript. The hybridized DO pairs are then ligated, forming a DNA product that can be amplified and sequenced. This innovative method enables specific and sensitive detection of gene expression, with the capability to target small numbers of transcripts or the entire transcriptome.
Joel McComb, Chief Executive Officer of BioSpyder, commented, "The launch of TempO-LINC represents a powerful approach to single-cell genomics. By leveraging the strengths of TempO-Seq technology, this platform offers numerous advantages, from greater gene discovery rates to the ability to assay gene expression on fixed cells stored in the freezer."
3 Simple Steps for customers:
Fix the cells with the provided fixation kit. (Our current available fixation kit sizes are for 12, 24 and 48 samples)
Ship samples in pre-addressed dry ice box
Receive the final sequencing data in demultiplexed single-cell count tables with a comprehensive bioinformatics report.
Unlike droplet-based methods, which face limitations with microfluidic processing and sample volumes, TempO-LINC offers a scalable approach limited only by the number of barcodes used. Accordingly, the assay is easily configurable for different cell throughputs and up to 48 samples.
Furthermore, BioSpyder is pleased to announce that TempO-LINC will be offered as a service through BioClavis, a BioSpyder spinoff company based in Scotland. BioSpyder Head of Strategy, Dennis Eastburn added, "Early access work with customers has demonstrated the utility of TempO-LINC across multiple applications. Now, our partnership with BioClavis ensures that TempO-LINC's transformative capabilities will be available as an easy-to-use service, broadening its reach and impact in the global scientific community."
For more information about TempO-LINC and BioSpyder's innovative technologies, please visit our website.
About BioSpyder: BioSpyder is a leading provider of advanced molecular biology technologies, committed to expanding scientific capabilities in toxicology, cancer biology, and environmental health. The company's TempO-Seq platform and related approaches continue to shape the landscape of genomics research, facilitating breakthroughs in drug discovery, translational research, and diagnostics.
About BioClavis: BioClavis, is a strategic partner of BioSpyder. Specializing in precision medicine and drug discovery, BioClavis extends the use of advanced molecular biology technologies, making them accessible for researchers and healthcare providers.